Cyclosporine in the treatment of dermatologie disease: An update

67Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Treatment with cyclosporine is beneficial for many dermatologie diseases such as psoriasis, lichen planus, Behçet disease, atopic dermatitis, pyoderma gangrenosum, and epidermolysis bullosa acquisita. The selective action of cyclosporine on helper T cells and its rapid therapeutic action and weak myelotoxicity are the key advantages in the treatment of many dermatologie diseases. Nevertheless, drug toxicity, especially nephrotoxicity, high rates of relapse after treatment cessation, and high cost have limited its use to those diseases refractory to other therapies. Herein we discuss the use of cyclosporine for dermato-logic diseases relative to efficacy, dosage, safety profile, and monitoring. In addition, we review the formulations and metabolism of cyclosporine; discuss its mechanism of action, clinical indications in dermatology, and side effects; and provide usage guidelines for this drug. Cyclosporine can be safely administered when potential toxicities, dosing, and monitoring guidelines are known. © 1996 Mayo Foundation for Medical Education and Research.

Cite

CITATION STYLE

APA

Lim, K. K., Daniel, W. P., Schroeter, A. L., Sabers, C. J., Abraham, R. T., & Pittelkow, M. R. (1996). Cyclosporine in the treatment of dermatologie disease: An update. Mayo Clinic Proceedings. Elsevier Ltd. https://doi.org/10.4065/71.12.1182

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free